Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It consists of the biologically active first 29 amino acids of endogenous human GHRH and is also known as GHRH(1-29)-NH₂.
Sermorelin stimulates the pituitary gland to release the body’s own growth hormone (GH). Increased GH secretion may then increase production of insulin-like growth factor-1 (IGF-1), which is involved in growth, metabolism, body composition, tissue repair, and other physiologic processes.
Sermorelin was previously marketed in the United States under the brand name Geref®. Geref was approved by the FDA in 1997 but was later discontinued. The FDA determined that Geref was not withdrawn for reasons of safety or effectiveness.
Sermorelin acts by binding to GHRH receptors on pituitary somatotroph cells. This stimulates endogenous, pulsatile growth hormone secretion.
Activation of the GHRH receptor may result in:
Unlike recombinant human growth hormone, sermorelin does not replace GH directly. Instead, it stimulates the pituitary gland to release GH through a more physiologic pathway.
The GH/IGF-1 axis governs two primary biological functions: Somatic Growth and Metabolism.
Growth (Somatic & Linear)
Metabolism
Potential benefits of sermorelin are related to increased endogenous GH and IGF-1 signaling.
Possible benefits may include:
It is important to note that many wellness-related uses of sermorelin are off-label and are not FDA-approved. Sermorelin is not FDA-approved for anti-aging, bodybuilding, weight loss, athletic performance, or longevity therapy.
Sermorelin may cause side effects, especially when used without appropriate medical supervision.
Potential risks and side effects include:
Because sermorelin stimulates GH and IGF-1 signaling, caution is appropriate in patients with diabetes, prediabetes, elevated IGF-1, unexplained edema, or a history of malignancy.
Sermorelin should generally be avoided or used only with caution in individuals with:
Patients considering sermorelin should undergo medical evaluation and monitoring, including assessment of symptoms, medical history, medications, glucose metabolism, and IGF-1 levels when clinically appropriate.
Sermorelin was previously FDA-approved under the brand name Geref®. The FDA orphan drug database lists sermorelin acetate / Geref with a marketing approval date of September 26, 1997.
Geref was later discontinued in the United States. In 2013, the FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness.
Current important points:
Human Studies
Sermorelin and related GHRH(1-29) analogs have been studied in both children and adults.
Clinical studies have evaluated sermorelin/GHRH therapy for:
A review article describes sermorelin as a 29-amino-acid analog of human GHRH and the shortest synthetic peptide retaining full biologic activity of GHRH.
In children with growth hormone deficiency, once-daily subcutaneous GHRH therapy was shown to accelerate growth during the first year of therapy.
In older adults, nightly administration of a GHRH analog for four months activated the somatotropic axis, increasing GH and IGF-1 activity.
Animal & Preclinical Studies
Preclinical research on GHRH analogs has helped establish their biologic activity and receptor-mediated effects.
Animal and laboratory studies have shown that GHRH analogs can:
Animal and preclinical data support the biologic plausibility of sermorelin, but they do not establish safety or effectiveness for common off-label wellness uses in humans.
Human Studies
Regulatory / FDA Sources
Review Articles & Scientific Background
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and reviewed for general accuracy; however, it may contain errors or omissions and should not replace professional medical judgment. Individuals should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# MK-677 (Ibutamoren)